Written by Support on 23 August 2018. Posted in Presse- & Adhoc-Mitteilungen. PM: Heidelberg Pharma AG: Partner Telix Pharmaceuticals beantragt Phase-III-Studie für bildgebende Nierenkrebs-Diagnostik in Europa PDF File: images/files/presse-adhoc-mitteilungen/2022/6373fcc86d3e5_20180823_Heidelberg-Pharma_PR_Telix_Ph-III_DE_Final.pdf 2018 Created on 15 November 2022. Last updated on 15 November 2022. Hits: 1340 Prev Next